An interventional study of Cholecystoscopy and gallbladder cleaning in Acute Cholecystitis, sponsored by Hospital General Universitario de Alicante. Recruiting at 2 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-10.
Sponsored by Hospital General Universitario de Alicante · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Cholecystitis, Acute with a site in Spain — 7 open to participants now, 7 under way, none of them phase 3. Cholecystitis, Acute · Spain.
Among the 13 studies in Cholecystitis, Acute with a site in Spain, this one is one of 2 that started in 2025, is one of 5 with no phase, and was the 10th registered.
140 studies on the registry are indexed under Cholecystitis, Acute; 30 are open to participants now.
Browse Cholecystitis, Acute studies →7 of the 13 studies in Cholecystitis, Acute with a site in Spain are open now. Recruiting first, the newest first:
Instituto de Investigación Sanitaria y Biomédica de Alicante · Sites in Spain
Ages 70+
Hospital Arnau de Vilanova · Sites in Spain
Ages 18+
Corporacion Parc Tauli · Sites in Spain
Ages 18–100
Fundacion Miguel Servet · Sites in Spain
Hospital del Mar · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 21 Cholecystitis, Acute studies recruiting now, 17 (81%) set no upper age limit and 2 (10%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 1 · Phase 4 1
First in 2013; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 82 is close to the median of 90 across 84 interventional studies indexed under Cholecystitis, Acute.
Median enrollment 146 across the 8 interventional studies, 600 across the 5 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 13 have an industry lead sponsor. The 10 most frequent:
Hospital General Universitario de Alicante is the lead sponsor of 13 studies on the registry; 5 are open to participants now.
Hospital General Universitario de Alicante has 2 studies filed under Cholecystitis, Acute — fewer than ten, so there is no comparison to draw.
2 of the studies in Cholecystitis, Acute with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07481760Hospital del MarAcute Cholecystitis Biliary Complications - ICG | 2027-01-01 |
| NCT07006298Instituto de Investigación Sanitaria y Biomédica de AlicanteOne-year Outcomes by Index Treatment in Elderly Patients With Acute Cholecystitis | 2027-05-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Cholecystitis, Acute with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patients with gallbladder inflammation (acute cholecystitis) who cannot undergo surgery due to their fragility and surgical risk require a gallbladder drainage. It has been confirmed in previous studies that the gallbladder drainage from the digestive tract is a better alternative, because it has fewer complications than external (percutaneous) gallbladder drainage. However, there are no known studies that demonstrate whether it is better to maintain this drainage indefinitely, or to carry out periodic revisions of the drainage to progressively remove the stones lodged in the gallbladder and remove the drainage once this has been achieved. In this study we aim to compare the clinical evolution of patients who undergo this gallbladder drainage, dividing them into two groups:
Knowledge of whether one strategy or the other presents fewer complications in the short, medium and long term is essential to be able to offer the best alternative to our patients.
The aim of the study is to compare the clinical outcome of these patients who have a definitive drain inserted with those who undergo several procedures to clear the gallbladder until the drain is removed. The rate of complications, the need for re-interventions and hospital admissions, new episodes of acute cholecystitis, quality of life and mortality of both groups over a period of one year are compared.
Laparoscopic cholecystectomy is the gold standard for treating acute cholecystitis (AC). However, not all patients are suitable candidates for surgery during an AC episode. After recovery, some may improve sufficiently to undergo preventive surgery for future biliary events, while others remain high-risk surgical candidates or fail to recover adequately, making surgery infeasible. For these high-risk patients, optimal management remains uncertain. Currently, percutaneous drainage is the standard treatment, with endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) emerging as a viable alternative in specialized centers. Recent data suggest that EUS-GBD may result in fewer complications compared to percutaneous drainage, with similar technical and clinical success rates.
Despite its promise, the optimal follow-up strategy for patients treated with EUS-GBD remains unclear, particularly regarding long-term complications associated with lumen-apposing metal stents (LAMS). Studies in pancreatic fluid collections suggest higher rates of complications, including bleeding and stent obstruction, leading to recommendations for early stent removal. However, for gallbladder drainage, the question arises whether LAMS should be maintained to prevent recurrence or replaced with less complication-prone stents like double pigtail stents.
The available evidence is contradictory. Some studies favor proactive endoscopic follow-up and gallstone removal to minimize recurrent cholecystitis, while others suggest that leaving LAMS indefinitely may reduce biliary events and hospital visits. To resolve these discrepancies, randomized prospective trials are needed to determine the optimal follow-up protocol for high-risk patients undergoing EUS-GBD for AC.
Our working hypothesis is that after EUS-GBD using a LAMS, there are no significant differences in the rate of biliopancreatic events between an active endoscopic approach (including gallbladder cleaning, stone extraction, and stent removal) and a conservative approach (without planned endoscopic interventions). Some studies even suggest that the proactive approach may lead to more complications The primary aim is to compare the rate of biliopancreatic events during one year of follow-up between patients treated with a proactive endoscopic strategy (group A) and those treated with a conservative strategy (group B) after EUS-GBD for acute cholecystitis (AC).
Secondary objectives focus on the evaluation of additional clinical outcomes, including complication rates at various time points, recurrence of biliary-related events, unplanned re-interventions, readmissions, mortality, disease-free survival, resolution of AC, and quality of life between the two groups.
This is a randomized, multicenter, open-label, nationwide, clinical trial. Patients will be randomized 1:1 to the two treatment groups stratified by center.
Centers eligible to participate as collaborating centers must have confirmed experience in EUS-guided procedures with EUS-GBD availability, having performed more than 10 EUS-GBD procedures prior to enrollment. Patient inclusion and exclusion criteria are specified in a separate section of the protocol.
For enrollment of patients, after diagnosis of AC, a patient evaluation by the surgical team or anesthesiologist declaring the patient unfit for surgery and the patient's willingness to undergo the EUS-GBD procedure is mandatory.
If the patient meets these requirements in addition to all previous inclusion criteria and none of the exclusion criteria, agrees to participate in the study, and signs the informed consent, the patient will be enrolled and randomized.
The randomization of patients to each of the treatment groups will be carried out centrally by the REDCap software; REDCap is a program that offers an online electronic data collection notebook. It will be stratified by center and by severity.
Patients will be randomized to two groups: Elective cholecystoscopy with stone extraction, eventual LAMS removal and double pigtail plastic stent (DPPS) placement or conservative management (indwelling LAMS). A total of 41 patients will be assigned to each group. In the group assigned to receive endoscopic interventions, upper gastrointestinal endoscopy will be programmed 4 weeks after de EUS-GBD and sequential procedures weekly thereafter until complete clearance of stones is achieved and the LAMS is removed and replaced with DPPS.
The procedure will be performed after at least 6 hours of fasting during the index admission, by endoscopists in charge of performing ERCP as usual in the collaborating centers under sedation controlled by endoscopists or anaesthesia according to the usual practice of the Endoscopy Unit of each collaborating center.
Gallbladder drainage will be performed with a LAMS, with a preference for stents ≥15 mm in diameter, and the preferred route will be duodenal (cholecystoduodenostomy); however, the final decision regarding stent size and route will be at the operator's discretion. After placement of the LAMS, a coaxial DPPS is placed. The DPPS complements the drainage and prevents complications.
After confirmation that the patient meets the inclusion criteria and none of the exclusion criteria, and after signing the informed consent form, the patient will undergo gallbladder drainage with a LAMS. The patient will then be randomized at their hospital to either group A (proactive treatment) or group B (conservative treatment). Randomization will not occur until after the drainage procedure has been completed.
Patient randomization in this clinical trial will be stratified by center to ensure an equal distribution of patients between the two intervention groups (proactive and conservative approaches) at each participating hospital. This stratification is essential to minimize potential center-specific differences that could influence outcomes.
Randomization sequences will be pre-generated using specialized software with blocks of four patients. Each block will randomly assign two patients to the proactive intervention group and two to the conservative group. This block design ensures that within each center, patients are sequentially and evenly assigned to both groups throughout the recruitment process, maintaining a constant balance. This approach is particularly critical because the trial may be stopped before the full expected sample size is reached.
The in-hospital management of patients with AC after EUS-GBD will be under the care of their attending physicians in the in-hospital ward of the respective collaborating center, who will follow the management recommended by the clinical guidelines. Their discharge will be decided by their regular physician. A clinical evaluation and laboratory tests will be performed 1 day and 7 days after the procedure (if the patient has not been discharged yet).
Periodic follow-up contacts are made: at 1 month, 6 months, 9 months, and 1 year. Contacts may be made by face-to-face or telematic visits after consultation with the patient, especially if the patient is institutionalized or has severe mobility problems. Additional laboratory tests are performed at the 1-month, 6-month and 1-year visits.
At these contacts, complications related to treatment and biliopancreatic events (BPE) that have occurred since the last visit are recorded. An interview will be conducted to record the presence of BPE that did not require admission (such as biliary colic or associated pain), recording the type and date of onset. The digital medical record will also be reviewed to record admissions and emergency department evaluations related or unrelated to BPE and to assess mortality.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Elective upper gastrointestinal endoscopy to perform cholecystoscopy, cleaning and removal of gallbladder (GB) stones and retrieval of the Lumen Apposing Metal Stent (LAMS) will be conducted 1 month after endoscopic ultrasound-guided GB drainage. For persistent GB stones, consecutive procedures will be performed weekly until complete cleaning and retrieval of the LAMS. A coaxial double pigtail plastic stent (7 or 10 Fr x 3 cm) will be placed indefinitely to maintain the fistula between the GB and the digestive tract.
Procedure: Cholecystoscopy and gallbladder cleaning
Patients in the conservative group will not be scheduled for endoscopic revision during the one-year follow-up. The LAMS will only be reviewed as part of routine practice for suspected LAMS related complications
Upper gastrointestinal endoscopy and cholecystoscopy are performed 4 weeks after GB drainage. A standard gastroscope is used to inspect the gallbladder cavity with retrieval or lithotripsy of residual stones until complete cleaning of the GB is achieved. Several procedures may be required to achieve complete stone clearance. Finally, the LAMS is retrieved and replaced with a double pigtail plastic stent.
Biliopancreatic events (BPE)
The primary aim is to assess the difference in terms of recurrence of the combined variable of biliopancreatic events (biliary colic, cholangitis, choledocholithiasis, acute cholecystitis or acute pancreatitis) between the active treatment group and the conservative treatment group during follow-up period.
Time frame: From enrollment until 12 months after
Recurrence of each of the variables that make up the combined variable BPE separately
To assess and compare the recurrence of each individual variable that constitutes the combined variable BPE across groups (AP, cholangitis, choledocholithiasis, cholecystitis, biliary colic)
Time frame: From enrollment until 12 months after
Total complication rate
The proportion of patients experiencing one or more complications during the study period
Time frame: From enrollment until 12 months after
Unplanned reintervention rate
The percentage of patients requiring unplanned additional surgical, radiologic or endoscopic interventions
Time frame: From enrollment until 12 months after
Biliary cause admission rate
The proportion of patients admitted to the hospital for biliary-related conditions
Time frame: From enrollment until 12 months after
Disease-Free survival
The time from treatment initiation to disease recurrence or death from any cause
Time frame: From enrollment until 12 months after
Mortality rate
The proportion of patients who die during the study period or within a defined follow-up time
Time frame: From enrollment until 12 months after
Recurrence rate of cholecystitis
The proportion of patients experiencing a new episode of cholecystitis after initial resolution
Time frame: From enrollment until 12 months after
Clinical Success Rate for the Resolution of Cholecystitis
The percentage of patients achieving complete resolution of cholecystitis symptoms with treatment
Time frame: From enrollment until 12 months after
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.
Of 43 non-industry interventional studies with no phase under Cholecystitis, Acute, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's planned 12 months is below that.
Counting every sponsor, half of 46 studies reached it within 20 months; a quarter within 9 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital General Universitario de Alicante